Literature DB >> 27106789

mTORC2 mediates CXCL12-induced angiogenesis.

Mary E Ziegler1, Michaela M S Hatch1, Nan Wu1, Steven A Muawad1, Christopher C W Hughes2,3,4.   

Abstract

The chemokine CXCL12, through its receptor CXCR4, positively regulates angiogenesis by promoting endothelial cell (EC) migration and tube formation. However, the relevant downstream signaling pathways in EC have not been defined. Similarly, the upstream activators of mTORC2 signaling in EC are also poorly defined. Here, we demonstrate for the first time that CXCL12 regulation of angiogenesis requires mTORC2 but not mTORC1. We find that CXCR4 signaling activates mTORC2 as indicated by phosphorylation of serine 473 on Akt and does so through a G-protein- and PI3K-dependent pathway. Significantly, independent disruption of the mTOR complexes by drugs or multiple independent siRNAs reveals that mTORC2, but not mTORC1, is required for microvascular sprouting in a 3D in vitro angiogenesis model. Importantly, in a mouse model, both tumor angiogenesis and tumor volume are significantly reduced only when mTORC2 is inhibited. Finally, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), which is a key regulator of glycolytic flux, is required for microvascular sprouting in vitro, and its expression is reduced in vivo when mTORC2 is targeted. Taken together, these findings identify mTORC2 as a critical signaling nexus downstream of CXCL12/CXCR4 that represents a potential link between mTORC2, metabolic regulation, and angiogenesis.

Entities:  

Keywords:  Akt; Angiogenesis; CXCL12; CXCR4; mTOR; mTORC2

Mesh:

Substances:

Year:  2016        PMID: 27106789      PMCID: PMC4959910          DOI: 10.1007/s10456-016-9509-6

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  52 in total

1.  Role of PFKFB3-driven glycolysis in vessel sprouting.

Authors:  Katrien De Bock; Maria Georgiadou; Sandra Schoors; Anna Kuchnio; Brian W Wong; Anna Rita Cantelmo; Annelies Quaegebeur; Bart Ghesquière; Sandra Cauwenberghs; Guy Eelen; Li-Kun Phng; Inge Betz; Bieke Tembuyser; Katleen Brepoels; Jonathan Welti; Ilse Geudens; Inmaculada Segura; Bert Cruys; Franscesco Bifari; Ilaria Decimo; Raquel Blanco; Sabine Wyns; Jeroen Vangindertael; Susana Rocha; Russel T Collins; Sebastian Munck; Dirk Daelemans; Hiromi Imamura; Roland Devlieger; Mark Rider; Paul P Van Veldhoven; Frans Schuit; Ramon Bartrons; Johan Hofkens; Peter Fraisl; Sucheta Telang; Ralph J Deberardinis; Luc Schoonjans; Stefan Vinckier; Jason Chesney; Holger Gerhardt; Mieke Dewerchin; Peter Carmeliet
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

2.  An optimized three-dimensional in vitro model for the analysis of angiogenesis.

Authors:  Martin N Nakatsu; Christopher C W Hughes
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

3.  Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines.

Authors:  S K Gupta; P G Lysko; K Pillarisetti; E Ohlstein; J M Stadel
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

4.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

5.  The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes.

Authors:  Y Sotsios; G C Whittaker; J Westwick; S G Ward
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  Rheb binds and regulates the mTOR kinase.

Authors:  Xiaomeng Long; Yenshou Lin; Sara Ortiz-Vega; Kazuyoshi Yonezawa; Joseph Avruch
Journal:  Curr Biol       Date:  2005-04-26       Impact factor: 10.834

7.  P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration.

Authors:  Ivette Hernández-Negrete; Jorge Carretero-Ortega; Hans Rosenfeldt; Ricardo Hernández-García; J Victor Calderón-Salinas; Guadalupe Reyes-Cruz; J Silvio Gutkind; José Vázquez-Prado
Journal:  J Biol Chem       Date:  2007-06-12       Impact factor: 5.157

8.  Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells.

Authors:  Isaya Hashimoto; Keiichi Koizumi; Mikiko Tatematsu; Takayuki Minami; Seiji Cho; Nobuhiro Takeno; Akitoshi Nakashima; Hiroaki Sakurai; Shigeru Saito; Kazuhiro Tsukada; Ikuo Saiki
Journal:  Eur J Cancer       Date:  2008-03-28       Impact factor: 9.162

9.  Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase.

Authors:  E Van Schaftingen; L Hue; H G Hers
Journal:  Biochem J       Date:  1980-12-15       Impact factor: 3.857

10.  CXCR7 functions as a scavenger for CXCL12 and CXCL11.

Authors:  Ulrike Naumann; Elisabetta Cameroni; Monika Pruenster; Harsha Mahabaleshwar; Erez Raz; Hans-Günter Zerwes; Antal Rot; Marcus Thelen
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more
  22 in total

Review 1.  Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis.

Authors:  Sasha A Doodnauth; Sergio Grinstein; Michelle E Maxson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 2.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

3.  Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

Authors:  Lei Miao; Jingjing Li; Qi Liu; Richard Feng; Manisit Das; C Michael Lin; Tyler J Goodwin; Oleksandra Dorosheva; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2017-08-28       Impact factor: 15.881

4.  Recapitulating the human tumor microenvironment: Colon tumor-derived extracellular matrix promotes angiogenesis and tumor cell growth.

Authors:  Mónica Romero-López; Andrew L Trinh; Agua Sobrino; Michaela M S Hatch; Mark T Keating; Cristhian Fimbres; David E Lewis; Paul D Gershon; Elliot L Botvinick; Michelle Digman; John S Lowengrub; Christopher C W Hughes
Journal:  Biomaterials       Date:  2016-11-24       Impact factor: 12.479

5.  Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m6A demethylation of EIF4EBP1 and MLST8 mRNA.

Authors:  Le Zhang; Xiulan Su
Journal:  Cell Oncol (Dordr)       Date:  2022-05-17       Impact factor: 7.051

6.  Angiogenic Properties of Concentrated Growth Factors (CGFs): The Role of Soluble Factors and Cellular Components.

Authors:  Nadia Calabriso; Eleonora Stanca; Alessio Rochira; Fabrizio Damiano; Laura Giannotti; Benedetta Di Chiara Stanca; Marika Massaro; Egeria Scoditti; Christian Demitri; Paola Nitti; Andrea Palermo; Luisa Siculella; Maria Annunziata Carluccio
Journal:  Pharmaceutics       Date:  2021-04-29       Impact factor: 6.321

7.  CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells.

Authors:  Min Zhang; Lisha Qiu; Yanyan Zhang; Dongsheng Xu; Jialin C Zheng; Li Jiang
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 8.  The CCL20-CCR6 Axis in Cancer Progression.

Authors:  Suguru Kadomoto; Kouji Izumi; Atsushi Mizokami
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

Review 9.  Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.

Authors:  Sen Guo; Chu-Xia Deng
Journal:  Int J Biol Sci       Date:  2018-11-13       Impact factor: 6.580

10.  KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.

Authors:  Xinling Liu; Jiaqiu Li; Zhanju Wang; Jie Meng; Aihong Wang; Xiaofei Zhao; Qilu Xu; Zhen Cai; Zhenbo Hu
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.